FDA Approved Products

190 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:All NDA BLA ANDA

Lifecycle:Growth Peak LOE Approaching Post-LOE Launch Pre-Launch

Sort:Approval Date Name Competitive Pressure↓

Active:Lifecycle: GrowthClear all

Day One Biopharmaceuticals

ORAL · FOR SUSPENSION

intermediatehigh-risk myelofibrosis (MF)+3

tizanidine hydrochloride

ORAL · SOLUTION

spasticity in adults

clonidine hydrochloride

ORAL · SUSPENSION, EXTENDED RELEASE

Attention Deficit Hyperactivity Disorder (ADHD)adjunctive therapy to central nervous system (CNS) stimulant medications in pediatric patients 6 years of age+1

Amicus Therapeutics

ORAL · CAPSULE

nalmefene hydrochloride

sulopenem etzadroxil and probenecid

Iterum Therapeutics

uncomplicated urinary tract infections (uUTI) caused by the designated microorganisms Escherichia coliKlebsiella pneumoniae+2

PAXLOVID (COPACKAGED)

nirmatrelvir and ritonavir

mild-to-moderate coronavirus disease 2019 (COVID-19) in adultsincluding hospitalization+1

pemetrexed disodium

INTRAVENOUS · SOLUTION

non-small cell lung cancerlung cancer

older with Ph+ CML in chronic phasenewly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase

flotufolastat f-18

Blue Earth Diagnostics

INTRAVENOUS · SOLUTION

PYRIDOSTIGMINE BROMIDE

pyridostigmine bromide

ORAL · TABLET, EXTENDED RELEASE

INTRATHECAL · SOLUTION

pilocarpine hydrochloride

Orasis Pharmaceuticals

OPHTHALMIC · SOLUTION/DROPS

INTRAVENOUS · POWDER

Eli Lilly and Company

ORAL · CAPSULE

Syndax Pharmaceuticals

Madrigal Pharmaceuticals

ORAL · SOLUTION

INTRAMUSCULAR · FOR SUSPENSION, EXTENDED RELEASE

INJECTION · SOLUTION

naloxone hydrochloride

NASAL · SPRAY, METERED

← PreviousPage 6 of 8Next →